儿童MLL基因重排相关白血病的治疗进展  

Progress in treatment of MLL-rearranged leukemia in children

作　　者：顾振羽 夏静 李天宇[2] Gu Zhenyu;Xia Jing;Li Tianyu(Wuxi People′s Hospital,Nanjing Medical University,Wuxi 214000,Jiangsu Province,China;Department of Hematology,Wuxi Children′s Hospital,Wuxi 214000,Jiangsu Province,China)

机构地区：[1]南京医科大学附属无锡人民医院,214000 [2]无锡市儿童医院血液科,214000

出　　处：《国际输血及血液学杂志》2019年第2期165-169,共5页International Journal of Blood Transfusion and Hematology

摘　　要：MLL基因重排相关白血病是由于11q23染色体上的MLL基因发生重排所致,是儿童白血病的常见类型之一,其在临床可表现为急性淋巴细胞白血病(ALL)、急性髓细胞白血病(AML)、骨髓增生异常综合征和治疗相关性白血病。目前,MLL基因重排相关白血病的治疗以联合化疗和异基因造血干细胞移植(allo-HSCT)为主,患儿生存率有所提高,但是大部分MLL基因重排相关白血病患儿的治疗效果及预后不佳。而靶向治疗、免疫治疗有望成为儿童MLL基因重排相关白血病提升疗效、改善预后、提高生存率的新方案。本文拟就近年MLL基因重排相关白血病的治疗进展,尤其是靶向治疗的研究进展及其发展潜力进行综述。MLL-rearranged leukemia is caused by rearrangement of the MLL gene located on chromosome 11q23, which is one of the common types in childhood leukemia. It can be clinically manifested as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome, and treatment-related leukemia. At present, the treatments of MLL-rearranged leukemia are combined chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT). The survival rate has been improved, but the outcomes and prognosis of most MLL-rearrangement leukemia are not excellent. Targeted therapy and immunotherapy are expected to become new treatments for the disease, which improve prognosis and survival rate. This article reviews the progress in the treatment of MLL-rearranged leukemia, and highlights the progress and potential of targeted therapy in recent years.

关 键 词：白血病 基因重排 抗肿瘤联合化疗方案 造血干细胞移植 分子靶向治疗 免疫疗法 MLL基因 

分 类 号：R733.7[医药卫生—肿瘤]